Kristen E Rhodin1, Vignesh Raman2, Oliver K Jawitz2, Betty C Tong3, David H Harpole3, Thomas A D'Amico3. 1. Department of Surgery, Duke University Medical Center, Durham, North Carolina. Electronic address: kristen.rhodin@duke.edu. 2. Department of Surgery, Duke University Medical Center, Durham, North Carolina. 3. Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Abstract
BACKGROUND: Adjuvant chemotherapy (AC) after esophagectomy improves survival in esophageal cancer when induction therapy is not given; however, the optimal timing for initiation of AC is poorly characterized. We aimed to determine the impact of timing of AC on survival after esophagectomy. METHODS: The National Cancer Database was queried for patients with pT1-4aNxM0 esophageal cancer receiving AC with or without radiation from 2004 to 2015. The median and interquartile range of time to AC were determined. Patients were stratified by initiation of AC into 4 cohorts based on quartiles. Kaplan-Meier curves were generated and factors associated with survival were identified by Cox proportional hazards modeling. A separate analysis was performed with time to AC as a continuous variable. RESULTS: A total of 1634 patients received AC after esophagectomy. Median time to receipt of AC was 59 (interquartile range, 45-78) days. There was no significant difference in overall survival at 5 years (P = .86) between groups. Median survival was 29 months in those receiving AC within 45 days and was 28 months in those receiving AC at other time points. On multivariable analysis, delay in receipt of AC beyond 45 days was not associated with inferior survival. This was preserved when time to AC was analyzed as a continuous variable (hazard ratio, 1.0; 95% confidence interval, 1.0-1.0). CONCLUSIONS: Timing of initiation of AC after esophagectomy does not appear to impact survival. Given the highly variable postoperative course after esophagectomy, the decision to start AC should involve multidisciplinary discussion and be made on a patient-by-patient basis.
BACKGROUND: Adjuvant chemotherapy (AC) after esophagectomy improves survival in esophageal cancer when induction therapy is not given; however, the optimal timing for initiation of AC is poorly characterized. We aimed to determine the impact of timing of AC on survival after esophagectomy. METHODS: The National Cancer Database was queried for patients with pT1-4aNxM0 esophageal cancer receiving AC with or without radiation from 2004 to 2015. The median and interquartile range of time to AC were determined. Patients were stratified by initiation of AC into 4 cohorts based on quartiles. Kaplan-Meier curves were generated and factors associated with survival were identified by Cox proportional hazards modeling. A separate analysis was performed with time to AC as a continuous variable. RESULTS: A total of 1634 patients received AC after esophagectomy. Median time to receipt of AC was 59 (interquartile range, 45-78) days. There was no significant difference in overall survival at 5 years (P = .86) between groups. Median survival was 29 months in those receiving AC within 45 days and was 28 months in those receiving AC at other time points. On multivariable analysis, delay in receipt of AC beyond 45 days was not associated with inferior survival. This was preserved when time to AC was analyzed as a continuous variable (hazard ratio, 1.0; 95% confidence interval, 1.0-1.0). CONCLUSIONS: Timing of initiation of AC after esophagectomy does not appear to impact survival. Given the highly variable postoperative course after esophagectomy, the decision to start AC should involve multidisciplinary discussion and be made on a patient-by-patient basis.
Authors: James J Biagi; Michael J Raphael; William J Mackillop; Weidong Kong; Will D King; Christopher M Booth Journal: JAMA Date: 2011-06-08 Impact factor: 56.272
Authors: Daniel P Raymond; Christopher W Seder; Cameron D Wright; Mitchell J Magee; Andrzej S Kosinski; Stephen D Cassivi; Eric L Grogan; Shanda H Blackmon; Mark S Allen; Bernard J Park; William R Burfeind; Andrew C Chang; Malcolm M DeCamp; David W Wormuth; Felix G Fernandez; Benjamin D Kozower Journal: Ann Thorac Surg Date: 2016-05-28 Impact factor: 4.330
Authors: David N Ranney; Michael S Mulvihill; Babatunde A Yerokun; Zachary Fitch; Zhifei Sun; Chi-Fu Yang; Thomas A D'Amico; Matthew G Hartwig Journal: Eur J Cardiothorac Surg Date: 2017-09-01 Impact factor: 4.191
Authors: J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson Journal: N Engl J Med Date: 2001-09-06 Impact factor: 91.245
Authors: James D Luketich; Arjun Pennathur; Yoko Franchetti; Paul J Catalano; Scott Swanson; David J Sugarbaker; Alberto De Hoyos; Michael A Maddaus; Ninh T Nguyen; Al B Benson; Hiran C Fernando Journal: Ann Surg Date: 2015-04 Impact factor: 12.969
Authors: Megan C Turner; Norma E Farrow; Kristen E Rhodin; Zhifei Sun; Mohamed A Adam; Christopher R Mantyh; John Migaly Journal: J Am Coll Surg Date: 2018-01-31 Impact factor: 6.113
Authors: Stephen R Smalley; Jacqueline K Benedetti; Daniel G Haller; Scott A Hundahl; Norman C Estes; Jaffer A Ajani; Leonard L Gunderson; Bryan Goldman; James A Martenson; J Milburn Jessup; Grant N Stemmermann; Charles D Blanke; John S Macdonald Journal: J Clin Oncol Date: 2012-05-14 Impact factor: 44.544
Authors: Christopher M Booth; Frances A Shepherd; Yingwei Peng; Gail Darling; Gavin Li; Weidong Kong; James J Biagi; William J Mackillop Journal: Cancer Date: 2012-11-06 Impact factor: 6.860